Sorrento Therapeutics Inc. shareholders lack grounds to appeal a bankruptcy court’s decision blocking a broad probe into whether company attorneys sought to exploit a romantic relationship involving ...

As a BCMA-targeting CAR T-cell therapy, CARVYKTI addresses a high unmet need in relapsed or refractory multiple myeloma patients. With promising clinical efficacy, durable responses, and growing ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

Equities researchers at StockNews.com started coverage on shares of Sorrento Therapeutics (NASDAQ:SRNE – Get Free Report) in a research report issued on Sunday. The firm set a “hold” rating on the ...